The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.
about
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group ReportMeasures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusOmega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus.Lipid anti-lipid antibody responses correlate with disease activity in systemic lupus erythematosusEfficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).A meta-analysis of public microarray data identifies gene regulatory pathways deregulated in peripheral blood mononuclear cells from individuals with Systemic Lupus Erythematosus compared to those withoutInitial validation of a novel protein biomarker panel for active pediatric lupus nephritis.Validation of the Spanish, Portuguese and French versions of the Lupus Damage Index questionnaire: data from North and South America, Spain and PortugalA prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus.Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus.Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus.Cell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside.Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical studyThe use of immunosuppressive and cytotoxic drugs in non-malignant disease.Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus.Clinical and immunologic manifestations of mixed connective tissue disease in a Miami population compared to a Midwestern US Caucasian populationSerological and genetic characterization of a human monoclonal immunoglobulin G anti-DNA idiotypeProspective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosusData quality challenges in systemic lupus erythematosus trials: how can this be optimized?Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritisPharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosusToward the development of criteria for global flares in juvenile systemic lupus erythematosusNeutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity.Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosusUnderexpression of mitochondrial-DNA encoded ATP synthesis-related genes and DNA repair genes in systemic lupus erythematosus.IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study.Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays.Preliminary criteria for global flares in childhood-onset systemic lupus erythematosusPreliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instrumentsAssessment of patients with idiopathic inflammatory myopathies and isolated creatin-kinase elevation.Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.How to monitor SLE in routine clinical practice.Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemiaSystemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time.Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study.B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study.Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels.
P2860
Q26827651-79D9E0D3-2968-4C61-B3F3-293ACE1F6018Q27021322-9A3806CA-99D6-407D-8C6A-C83CBBA037E8Q28254310-C7C3AEBB-CADB-43E6-9C73-986A6D3C3F3DQ30409882-2AA1CAFD-E767-45AB-9756-842A3544AB4AQ30588683-C479065B-B6E0-4250-BE2B-9C0AF94F9C2BQ30832522-E953371A-A61C-40E8-9294-F4EF7E33F288Q31142463-A87515F0-DF8F-4D04-9FED-2C4C8228D242Q33409400-EC0E402F-A0D3-485F-ABE2-3016E8372458Q33504486-D53E5F5E-1611-4258-BC51-37424CC6554DQ33566318-09D40E58-4B70-4054-9EEE-565B2913657CQ33567006-2CA3EA86-362D-4C07-B8DB-6FF323B9798BQ33579349-35CC95EF-E816-40A3-88DD-EE36165FFB08Q33723371-2F958132-0586-4F3C-B02B-FB4F0C7D2722Q33767123-4B78AF81-299A-46A4-BEE0-AA6F664DA4FDQ34010757-1F5E5768-93C4-43BB-B26B-52C64B9FBCF3Q34046983-1C3BA4BD-3BF7-4C3D-ABD8-9BD93349BD6BQ34056359-2F3E57E7-B74A-4D75-8F88-C53B64BA9041Q34141241-CBD30A2E-4381-4289-ABB0-E07050072348Q34157817-91CC5C32-B47A-431C-B58E-EA6C000BD57AQ34267149-0C5CBB34-E382-4DA5-879C-CAEA859403C1Q34413203-3AC16A3F-A7C7-4C06-AC6E-8E2A0AD23480Q34494943-C344D4C7-2573-4146-BEA5-ED59057C09BBQ34626276-C39C1736-830C-4EEB-B862-7A37B04973C2Q34720014-00DD3E9D-BA9B-4BFF-AC3A-88261B863C51Q34897437-D99DDF59-60FB-4798-A2F3-F375272B3C7CQ35093017-BCF47A76-768C-4D40-B5F5-9B05327C75A0Q35162593-7B07A170-6674-4055-9326-9E1768BB330CQ35194106-437B2148-5A46-4D3F-9499-14C4FA5278B6Q35199345-D3C8E5C7-1B3E-475E-BE66-F7C12679EBCDQ35229292-960CFFAA-C183-4E64-B01C-C646288FCA2BQ35281980-5F25D3E1-84A4-4277-AE7F-84B253F88940Q35555256-AF801431-9287-4243-AC79-81A6D85DB757Q35555460-F2C2ADE7-9136-479B-933A-4A6DD8C2AA5DQ35555688-9D06F76E-8090-4DD8-B09C-A7E463382049Q35637820-938690E2-D908-4E01-A80E-B875B99279F9Q35927877-5CDB44EB-F368-41E0-8176-F0A2F8763E97Q35954653-C015C41F-F8AA-4EE2-A17A-2173138429FFQ35960478-F2B3668A-47DE-4A04-8142-CCD7A47A0C0CQ35993027-52A3CA5C-573C-4989-9F5A-83DDAEA95CEEQ36049625-444A1DA0-BD32-4825-92EF-BD94C8A66B78
P2860
The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
The BILAG index: a reliable an ...... systemic lupus erythematosus.
@en
The BILAG index: a reliable an ...... systemic lupus erythematosus.
@nl
type
label
The BILAG index: a reliable an ...... systemic lupus erythematosus.
@en
The BILAG index: a reliable an ...... systemic lupus erythematosus.
@nl
prefLabel
The BILAG index: a reliable an ...... systemic lupus erythematosus.
@en
The BILAG index: a reliable an ...... systemic lupus erythematosus.
@nl
P2093
P1476
The BILAG index: a reliable an ...... systemic lupus erythematosus.
@en
P2093
Maddison P
Symmons DP
P304
P577
1993-07-01T00:00:00Z